Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76				Attorne	ey Docket Number 265/55				
				Applica	ation Num	ber			
Title of Invention Pharmaceutical Compositions, Methods Of Formulation Thereof And Methods Of Use Thereof									
bibliographic data	arranged in a ay be complet	format specifie ed electronica	ed by the U	inited States bmitted to t	Patent and	Trademark C	office as	ubmitted. The following form contains t outlined in 37 CFR 1.76. ing the Electronic Filing System (EFS	
Secrecy O	rder 37 (	CFR 5.2							
								fall under a Secrecy Order pursy not be filed electronically.)	suant to
Applicant I	nformat	tion:							
Applicant 1									
Applicant Aut	hority Oln	ventor	Legal Re	epresentati	ve under 3	5 U.S.C. 11	7	Party of Interest under 35 U.S.	C. 118
Prefix Given				Middle Na	me		Family Name		Suffix
Ephraii	n						Lansky		
Residence In	formation	(Select On	e) 🔾 U	S Residen	су 💿	Non US Re	sidenc	y Active US Military Service	
City Haifa			Cou	ntry Of R	esidence	IL			
Citizenship u	nder 37 CF	R 1.41(b) i	IL						
Mailing Addre	ess of Appl	icant:	<u>.</u>						
Address 1									
Address 2									
City Ha	nifa	<del>,</del>			S	ate/Provi	nce		
Postal Code					Countr	yi IL			
All Inventors generated with						n blocks	may l	be Add	
Correspon	dence l	nformat	ion:						
Enter either C For further in			•		responde	nce Infor	natior	section below.	
☐ An Addre	ess is being	g provided	for the	correspo	ndence Ir	formation	of th	is application.	
Customer Nu	mber	44696							
Email Addres	s							Add Email Remove.	Email
Application	n Inform	ation:							
Title of the Invention Pharmaceutical Compositions, Methods Of Formulation Thereof And Methods Of Use Thereof							f		
Attorney Doc	ttorney Docket Number 265/55 Small Entity Status Claimed 🔀								
Application T	уре	Nonprovi	sional						
Subject Matte	er								
Suggested Class (if any)									
Suggested Te	chnology	Center (if a	iny)					<u> </u>	
Total Number of Drawing Sheets (if any)  Suggested Figure for Publication (if any)									

PTO/SB/14 (08-05)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Officer die rapi	elwolk Ke	sauction Act of 1995, no per	sons are require	to respond to a conect	on or information	uniess il contains	s a valid Olvis Control Humber	
Application Data Sheet 37 CFR 1.7			Attorney Docket Number 26		265/55	265/55		
			Application	Application Number				
Title of Invention Pharmaceutical Compositions, Methods Of Formulation Thereof And Methods Of Use Thereof								
Publication Informa	tion:							
		tion (Fee required a	time of Re	guest 37 CER 1 1	210)	<del></del> -		
		<u> </u>		·		shed under	35 U.S.C. 122(b)	
Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not been and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.								
Representative Representative informathis information in the A	ation sh	nould be provided for on Data Sheet does n	ot constitute	a power of attorne	y in the applic	ney in the a	application. Providing CFR 1.32).	
Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.								
Please Select One:	(	Customer Number	OU	S Patent Practition	er O US	S Representa	tive (37 CFR 11.9)	
Customer Number	4	4696						
Domestic Priority Information:  This section allows for the applicant to claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c). Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a) (4), and need not otherwise be made part of the specification.								
Prior Application S		0	<b>-</b>	D. A. F.			move)	
Application Numb	er	Continuity	Гуре				ng Date (YYYY-MM-DD)	
· · · · · · · · · · · · · · · · · · ·				60555320		2004-03-23	<del></del>	
Additional Domestic the <b>Add</b> button.	Priority	y Data may be ger	erated witl	nin this form by s	selecting			
Foreign Priority	y Info	ormation:						
This section allows for t not claimed. Providing t and 37 CFR 1.55(a).	the appl this info	licant to claim benefit mation in the applica	of foreign pri tion data she	ority and to identify eet constitutes the c	any prior fore laim for priorit	ign applicatio y as required	n for which priority is by 35 U.S.C. 119(b)	
Re						move)		
Application Numb	er	Countr	y i	Parent Filing Date (YYYY-MM-DD)		MM-DD)	Priority Claimed	
PCT/IL2005/000332	_2005/000332			2005-03-23				
Additional Foreign Pr Add button.	riority [	Data may be genera	ated within	this form by selec	cting the			
Assignee Inform	matio	on:		-			-	
Providing this information of the CFR to have an a	on in the	e application data she nent recorded in the O	et does not : ffice.	substitute for compl	iance with any	requirement	of part 3 of Title 37	
Assignee 1								
If the Assignee is an	Organi	zation check here.	×			·		

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76			Attorney Docket Number Application Number		265/55		
Title of Invention	Pharm	aceutical Compositions, Methods Of Formulation Thereof And Methods Of Use Thereof					
Organization Name	e Ri	monest Ltd.					
Mailing Address							
Address 1 P.O.Box 9945							
Address 2							
City H		Haifa	9	State/Provi	nce		
Country   IL			F				
Phone Number			Fax Number				
Email Address							
Additional Assigne button.	e Data	may be generated v	vithin this form by	y selecting	the Add		

## Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.							
Signature	/MMF/		Date (YYYY-MM-DD) 2006-09-21				
First Name	Mark	Last Name	Friedman	Registration Number	33883		

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
  and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
  whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
  individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
  the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.